Incannex Healthcare (IXHL) Research & Development (2022 - 2026)

Incannex Healthcare has disclosed Research & Development across 5 years of filings, most recently posting $321000.0 for Q1 2026.

• In Q1 2026, Research & Development fell 88.26% year-over-year to $321000.0; the TTM figure through Mar 2026 stood at $7.4 million (down 34.91% YoY), while the FY2025 annual figure was $10.7 million, down 16.55% from the prior year.
• Research & Development came in at $321000.0 for Q1 2026 at Incannex Healthcare, down from $2.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $4.4 million in Q2 2024 to a low of $321000.0 in Q1 2026.
• Average Research & Development over 5 years is $2.3 million, with a median of $2.4 million recorded in 2023.
• Year-over-year, Research & Development jumped 154.61% in 2024 and tumbled 88.26% in 2026.
• Over 5 years, Research & Development stood at $1.5 million in 2022, then soared by 70.3% to $2.6 million in 2023, then sank by 46.4% to $1.4 million in 2024, then jumped by 61.24% to $2.3 million in 2025, then tumbled by 85.92% to $321000.0 in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $321000.0 in Q1 2026, $2.3 million in Q4 2025, and $1.1 million in Q3 2025.